source
- Novartis and Novo Nordisk see back-to-back cardiovascular trial failures, raising doubts for the fieldNovartis announced that its experimental heart‑protective therapy, pelacarsen, did not meet its primary endpoints in a seven‑year study designed to cut heart attacks and strokes by lowering lipopro…
- Novartis shares tumble 13% after three late-stage drug setbacks hit marketNovartis' stock dropped more than 13% this week after three of its late-stage programs reported setbacks, pulling down other pharma stocks. The antibody-oligonucleotide conjugate del-desiran faile…